Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnGraft
2020-000796-20Phase 4Active
- Sponsor
- Universitätsklinikum Regensburg
- Start
- May 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in Hepatic transplant rejection (LTR) (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Dose-normalised trough level (C/D ratio). Started May 2020; status: active.
02
Drugs
tacrolimus
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2020-000796-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000796-20.